Key result
In hospice patients with non-lung cancers, a natural logarithm-transformed high-frequency power (lnHFP) value below 2 at admission was significantly associated with a higher risk of survival of 7 days or less (OR 3.80).
Why the study?
Does heart rate variability predict 7-day survival in hospice patients with advanced non-lung cancers?
Population
138 hospice patients with advanced non-lung cancers recruited from a regional hospital in southern Taiwan
Design
Cohort
Follow-up
7 days (median survival 20 days)
Authors
Loading...
May refine short-term prognostication in non-lung cancer hospice patients; leaves open prospective validation before clinical adoption.
Cohort (n=138)
No
Does heart rate variability predict 7-day survival in hospice patients with advanced non-lung cancers?
Odds Ratio: 3.8 (95% CI 1.49–11.12)
p-value: p=0.008
In hospice patients with advanced non-lung cancers, reduced high-frequency heart rate variability (lnHFP < 2) is a significant predictor of mortality within 7 days.
Chiang et al. (2013) conducted a cohort in Advanced non-lung cancer (n=138). Natural logarithm-transformed high-frequency power (lnHFP) < 2 vs. lnHFP ≥ 2 was evaluated on Survival of 7 days or less (OR 3.80, 95% CI 1.49-11.12, p=0.008). In hospice patients with non-lung cancers, a natural logarithm-transformed high-frequency power (lnHFP) value below 2 at admission was significantly associated with a higher risk of survival of 7 days or less (OR 3.80).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: